1-3 of 3
Matthew Howard
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Maymona Abdelmagid, Aref Al-Kali, Kebede H. Begna, William J. Hogan, Mark R. Litzow, Abhishek A. Mangaonkar, Mrinal M.M. Patnaik, Michelle A Elliott, Hassan B. Alkhateeb, Min Shi, Matthew Howard, Kaaren K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Journal: Blood
Blood (2022) 140 (Supplement 1): 9735–9736.
https://doi.org/10.1182/blood-2022-163450
Published: 2022
Journal Articles

Adverse Factors in Clinical Outcomes of T-Cell Large Granular Lymphocyte Leukemia.

Nelli Bejanyan, MD, Aleksandr Lazaryan, MD, MPH, PhD, Michael Clemente, Matthew Howard, MD, Karl S. Theil, MD, Eric D. Hsi, MD, Thomas P. Loughran, Jr., MD, Alan Lichtin, MD, Jaroslaw P. Maciejewski, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1086.
https://doi.org/10.1182/blood.V114.22.1086.1086
Published: 2009
Journal Articles

A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.

Anjali Advani, MD, Edward A. Copelan, MD, Ronald Sobecks, MD, Mikkael A Sekeres, MD, MS, Jennifer Bates, Mary Lynn Rush, Barbara Tripp, Elysa Noon, PhD, Matthew Howard, MD, Tao Jin, Eric Hsi, MD, Matt Kalaycio, MD
Journal: Blood
Blood (2008) 112 (11): 955.
https://doi.org/10.1182/blood.V112.11.955.955
Published: 2008